General OA media and info, page-600

Interesting to see sentiment of the crowd here. The point of sharing turnaround stories is that almost all outsized gains starts with massive draw downs beforehand.

My investment thesis hasn't changed other than timelines. This is based on additional factual investigation and not share price lead sentiment. If it helps you vent (like it has for me a times) to blame PR for missteps then at some point you may also need to reflect on your own investment decision framework for biopharma.

IMO PAR is more focused than ever with refreshed team. Admittedly some luck is still required to get the regional deal done in time that shows we can monetise the OA asset.

Nevertheless I'm a buyer based on my observation of the crowd and clear intent of management.

p.s. thoughts of running out of cash and even fraud typically signals a pivot point.